Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects

Authors: Lei Wang, Zan Teng, Shuang Cai, Difei Wang, Xin Zhao, Kai Yu

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Background

The polymorphism Pro12Ala in peroxisome proliferator-activated receptor­γ2 gene (PPARγ2) has been reported to be associated with diabetic nephropathy (DN) in some studies, though the results remain inconclusive. To explore this relationship between PPARγ2 Pro12Ala polymorphism and the susceptibility for DN, a cumulative meta-analysis was performed in this study.

Method

PubMed, Medline, Embase and Web of Science databases have been systematically searched to identify relevant studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results

18 studies were included in this meta-analysis, involving 3,361 cases and 5,815 controls. The PPARγ2 Ala12 allele was significantly associated with decreased risk of DN based on dominant model (OR=0.778; 95%CI=0.618–0.981; Pheterogeneity=0.008; P=0.034). In the stratified analysis by ethnicity, significantly decreased risks were found among Caucasians for dominant model (OR=0.674; 95%CI=0.500–0.909; Pheterogeneity=0.079; P=0.010), while there was no significant association was found in Asians.

Conclusions

The results from the present meta-analysis indicated that the Pro12Ala polymorphism in PPARγ2 gene is not a risk factor for DN in type 2 diabetes (T2D). Further large and well-designed studies are needed to confirm this conclusion.

Virtual slides

The virtual slides for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​7491348341027320​.
Appendix
Available only for authorised users
Literature
1.
Ayodele OE, Alebiosu CO, Salako BL: Diabetic nephropathy: A review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004, 96: 1445-1454.PubMedCentralPubMed
2.
Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS: Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: Results of novel discordant sib-pair analysis. Diabetes. 1998, 47: 1164-1169. 10.2337/diabetes.47.7.1164.CrossRefPubMed
3.
Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD: Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol. 2001, 281: F1036-F1046.CrossRefPubMed
4.
Deeb SS, Fajas L, Nemoto M, et al.: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998, 20: 284-287. 10.1038/3099.CrossRefPubMed
5.
Liu L, Zheng T, Wang F, et al.: Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. DiabetesCare. 2010, 33: 144-149. 10.2337/dc09-1258.
6.
Argmann CA, Cock TA, Auwerx J: Peroxisome proliferator-activated receptor gamma: The more the merrier?. Eur J Clin Invest. 2005, 35: 82-92. 10.1111/j.1365-2362.2005.01456.x.CrossRefPubMed
7.
Desvergne B, Michalik L, Wahli W: Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Mol Endocrinol. 2004, 18: 1321-1332. 10.1210/me.2004-0088.CrossRefPubMed
8.
Caramori ML, Canani LH, Costa LA, Gross JL: The human peroxisome proliferator-activated receptor gamma2 (PPAR-gamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003, 52: 3010-3013. 10.2337/diabetes.52.12.3010.CrossRefPubMed
9.
Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E: Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002, 51: 2653-2657. 10.2337/diabetes.51.8.2653.CrossRefPubMed
10.
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000, 268: 178-182. 10.1006/bbrc.2000.2096.CrossRefPubMed
11.
Davey SG, Egger M: Meta-analyses of randomized controlled trials. Lancet. 1997, 350: 1182-
12.
Ioannidis JP, Boffetta P, Little J, et al.: Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008, 37: 120-132. 10.1093/ije/dym159.CrossRefPubMed
13.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. Natl Cancer Inst. 1959, 22: 719-778.
14.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
15.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1101. 10.2307/2533446.CrossRefPubMed
16.
Egger M, Smith DG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.PubMedCentralCrossRefPubMed
17.
Mori H, Ikegami H, Kawaguchi Y, et al.: The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001, 50: 891-894. 10.2337/diabetes.50.4.891.CrossRefPubMed
18.
Wu S: Study on the Relationship of Polymorphism of PPAR-g2 and Type 2 Diabetes and Diabetic Nephropathy. 2004, Tianjin: Tianjin Medical University
19.
Maeda A, Gohda T, Funabiki K, Horikoshi S, Tomino Y: Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal. 2004, 18: 317-321. 10.1002/jcla.20045.CrossRefPubMed
20.
Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ: Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications. 2007, 21: 166-171. 10.1016/j.jdiacomp.2006.02.006.CrossRefPubMed
21.
Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C: The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract. 2007, 78: 355-359. 10.1016/j.diabres.2007.06.005.CrossRefPubMed
22.
Wei F, Wang J, Wang C, Huo X, Xue Y, Bai L: The relationship between the pro12Ala polymorphism in PPAR-g2 gene and diabetic nephropathy in Baotou. Chinese J Diabetes. 2008, 16: 679-680.
23.
Li L, Liu L, Zheng T, Wang N, Wang F: Peroxisome proliferator activated receptor g2 gene P12A polymorphism and type 2 diabetic nephropathy in Han population in Shanghai. J Shanghai Jiaotong Univ. 2008, 28: 376-379.
24.
Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E: Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009, 24: 3360-3366. 10.1093/ndt/gfp271.CrossRefPubMed
25.
De Cosmo S, Motterlini N, Prudente S, et al.: BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes. 2009, 58: 2920-2929. 10.2337/db09-0407.PubMedCentralCrossRefPubMed
26.
Liu L, Zheng T, Wang F, et al.: Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care. 2010, 33: 144-149. 10.2337/dc09-1258.PubMedCentralCrossRefPubMed
27.
Lapice E, Pinelli M, Riccardi G, Vaccaro O: Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care. 2010, 33: e114-10.2337/dc10-0596.CrossRefPubMed
28.
Zhu W, Ji Y, Bu L, Yang Q: The correlativity study of peroxisome proliferator activated receptor g2 gene polymorphism with susceptibility of diabetic nephropathy in type 2 diabetes mellitus. J Radio-immunology. 2011, 24: 296-298.
29.
De Cosmo S, Prudente S, Lamacchia O, et al.: PPAR{gamma}2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case–control studies. Nephrol Dial Transplant. 2011, 26: 4011-4016. 10.1093/ndt/gfr187.CrossRefPubMed
30.
Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H: Peroxisome Proliferator–Activated Receptor g Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes. Diabetes Care. 2012, 35: 1388-1393. 10.2337/dc11-2142.PubMedCentralCrossRefPubMed
31.
Fujisawa T, Ikegami H, Kawaguchi Y, et al.: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-con-verting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998, 41: 47-53. 10.1007/s001250050865.CrossRefPubMed
32.
Fei J, Li-Shuai Q, Xi-Zhong S: Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn Pathol. 2009, 4: 39-10.1186/1746-1596-4-39.CrossRef
33.
de Matos L, Adriana Del G, Carolina M, de Lima Farah M, Auro Del G, da Silva Pinhal M: Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012, 7: 97-10.1186/1746-1596-7-97.PubMedCentralCrossRefPubMed
34.
Xue Q, Qiliu P, Aiping Q, Zhiping C, Liwen L, Yan D, Li X, Juanjuan X, Haiwei L, Taijie L, Shan L, Jinmin Z: Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol. 2012, 7: 136-10.1186/1746-1596-7-136.CrossRef
35.
Liwa Y, Jianqiu C: Association of MHTFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies. Diagn Pathol. 2012, 7: 171-10.1186/1746-1596-7-171.CrossRef
Metadata
Title
The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects
Authors
Lei Wang
Zan Teng
Shuang Cai
Difei Wang
Xin Zhao
Kai Yu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-118

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Research

Deletion mutation in BSCL2 gene underlies congenital generalized lipodystrophy in a Pakistani family

Research

Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway

Case Report

Salivary adenoid cystic carcinoma with an early phase of high-grade transformation: case report with an immunohistochemical analysis

Research

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens

Case Report

Renal mucinous tubular and spindle cell carcinoma: a report of 8 cases and review of the literature

Research

Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors